Instrument Inactif

Communiqués Natco Pharma Ltd. NSE India S.E.

Actions

INE987B01018

Cours en clôture NSE India S.E. Autres places de cotation
- ^INR	-

28/05	ACTIONS INDIENNES - Les métaux et les valeurs pharmaceutiques tirent les indices indiens vers le haut	RE
28/05	Transcript : NATCO Pharma Limited, Q4 2024 Earnings Call, May 28, 2024

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Delhi High Court Refuses To Vacate Interim Injunction Granted In Favour Of Novartis For Compound Ceritinib	30/05	AQ
Patent Infringement In India: Recent Case Studies And Legal Updates	27/05	AQ
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid, in the U.S	10/03/23	AQ
The Doctrine Of Equivalents In Patent Law: An Analysis Of The FMC Corporation vs Natco Pharma Limited Judgment	09/02/23	AQ
Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	25/08/22	AQ
NATCO records INR 918.9 Crore consolidated revenue and INR 320.4 Crore of profit, after tax, for the First Quarter, FY2022-23	10/08/22	AQ
NATCO Pharma : Press Release	25/07/22	PU
NATCO Announces Launch of First Generic Version of Nexavar (Sorafenib) Tablets in the U.S. Market	02/06/22	AQ
NATCO records INR 2043.8 Crore consolidated revenue and INR 170.0 Crore of profit, after tax, for the year ended March 31' 2022	31/05/22	AQ
Natco Pharma - Edelweiss Securities invites you to Natco Pharma Q4 FY22 Earnings call	26/05/22	AQ
NATCO Announces Launch of the First Generic Version of Revlimid (Lenalidomide capsules), in the U.S. market	08/03/22	AQ
NATCO Pharma : Newspaper Advertisements	23/02/22	PU
NATCO Pharma : ESOP/ESOS/ESPS	28/01/22	PU
NATCO announces License Agreement with the Medicines Patent Pool	21/01/22	AQ
NATCO Pharma Limited has been awarded Corporate Governance Award07 January 2022	10/01/22	AQ
NATCO Pharma receives approval for Molnupiravir Capsules 200 mg for the treatment of Covid-19 in India	29/12/21	AQ
Natco Pharma : launches Everolimus tablets 10 mg in US market	04/10/21	AQ
NATCO Pharma : receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA ) ANDA in the US market	13/04/21	AQ
NATCO Pharma : forays into Pheromone based technology for Integrated Pest Management	16/03/21	AQ
NATCO Pharma : launches Brivaracetam tablets, in India, for treatment of epilepsy	01/03/21	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Natco Pharma Ltd. NSE India S.E.

Actions

INE987B01018

Communiqués

Filtres